Alogliptin Benzoate/Pioglitazone Hydrochloride

苯甲酸阿格列汀/盐酸吡格列酮

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAlogliptin Benzoate/Pioglitazone Hydrochloride
Drug Alias NamePioglitazone Hydrochloride/Alogliptin Benzoate盐酸吡格列酮/苯甲酸阿格列汀Alogliptin Benzoate and Pioglitazone HydrochlorideAlogliptin/PioglitazoneAlogliptin/Actos +[13] 
ClassificationSmall molecules
Mechanisms of ActionDipeptidyl peptidase IV inhibitorsPeroxisome proliferator-activated receptor γ agonists
TargetsDipeptidyl peptidase IVPeroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2011/07/01
Country/TerritoryUnited StatesEUJapan
CombinationsYes Alogliptin BenzoatePioglitazone Hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncTeijin Pharma LtdTakeda Pharmaceutical Co Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeA10BD09
Related LinksKEGG